In the BioHarmony Drug Report Database

"Preview" Icon

Trilaciclib

Cosela (trilaciclib) is a small molecule pharmaceutical. Trilaciclib was first approved as Cosela on 2021-02-12. It is known to target cyclin-dependent kinase 4, cyclin-dependent kinase 6, cyclin-dependent kinase 7, cyclin-dependent kinase 9, and cyclin-dependent kinase 2. Cosela’s patents are valid until 2034-03-14 (FDA).

 

Trade Name

 

Cosela
 

Common Name

 

trilaciclib
 

ChEMBL ID

 

CHEMBL3894860
 

Indication

 

 

Drug Class

 

Cyclin dependent kinase inhibitors

Image (chem structure or protein)

Trilaciclib structure rendering